ERBB2 and neoplasm: This phenomenon underscores the dynamic nature of tumor biology and the potential impact of treatment on tumor characteristics, although it remains unclear if discordance in HER2 status is due to tumor evolution and treatment-selective pressure, analytical factors in HER2 testing, or tumor heterogeneity which could have implications for therapeutic response and long-term outcomes in patients with eTNBC.